6,942 research outputs found
The Life and Letters of William Sharp and "Fiona Macleod"
Get PDF"William Sharp (1855-1905) conducted one of the most audacious literary deceptions of his or any time. Sharp was a Scottish poet, novelist, biographer and editor who in 1893 began to write critically and commercially successful books under the name Fiona Macleod. This was far more than just a pseudonym: he corresponded as Macleod, enlisting his sister to provide the handwriting and address, and for more than a decade ""Fiona Macleod"" duped not only the general public but such literary luminaries as William Butler Yeats and, in America, E. C. Stedman.
Sharp wrote ""I feel another self within me now more than ever; it is as if I were possessed by a spirit who must speak out"". This three-volume collection brings together Sharp’s own correspondence – a fascinating trove in its own right, by a Victorian man of letters who was on intimate terms with writers including Dante Gabriel Rossetti, Walter Pater, and George Meredith – and the Fiona Macleod letters, which bring to life Sharp’s intriguing ""second self"".
With an introduction and detailed notes by William F. Halloran, this richly rewarding collection offers a wonderful insight into the literary landscape of the time, while also investigating a strange and underappreciated phenomenon of late-nineteenth-century English literature. It is essential for scholars of the period, and it is an illuminating read for anyone interested in authorship and identity.
Dashboard as a commercial tool to monitor in real time Keytruda, the star product of the pharmaceutical company Merck Sharp & Dohme
No full textMerck Sharp & Dohme (MSD), una empresa farmacéutica estadounidense fundada en 1891, ha desempeñado un papel crucial en la invención de medicamentos que salvan vidas. Uno de sus avances más significativos ocurrió en 2014 con la aprobación por parte de la FDA de Keytruda, un tratamiento revolucionario para el cáncer. El impacto de Keytruda en la atención médica y el desempeño financiero de la empresa ha sido profundo. Este estudio explora los desafíos y complejidades de gestionar la alta demanda de Keytruda dentro de MSD.
El proyecto destaca la necesidad de desarrollar una herramienta de inteligencia empresarial dinámica, especialmente utilizando Microsoft Power BI, para extraer y visualizar de manera eficiente los extensos datos comerciales generados por la empresa. El objetivo de esta herramienta es proporcionar información en tiempo real que ayude en los procesos de toma de decisiones de la dirección. El estudio revisa literatura relevante, incluyendo el preprocesamiento de datos, tipos de paneles de control y principios de diseño, para guiar la construcción de un panel de control eficaz y fácil de usar para el análisis comercial de Keytruda.
En resumen, este proyecto ofrece una valiosa hoja de ruta para construir un panel de control eficiente basado en Microsoft Power BI que mejora los procesos de toma de decisiones comerciales de Keytruda, garantizando mejores resultados de atención médica para los pacientes con cáncer y un crecimiento sostenible del negocio para MSD.Merck Sharp & Dohme (MSD), an American pharmaceutical company founded in 1891, has played a crucial role in inventing life-saving medications. One of its most significant breakthroughs came in 2014 with the FDA approval of Keytruda, a groundbreaking treatment for cancer. Keytruda's impact on healthcare and the company's financial performance has been profound. This study explores the challenges and complexities of managing high demand for Keytruda within MSD.
The project emphasizes the need to develop a dynamic business intelligence tool, particularly using Microsoft Power BI, to efficiently extract and visualize the extensive commercial data generated by the company. The tool aims to provide real-time insights, aiding managerial decision-making processes. The study reviews relevant literature, including data preprocessing, dashboard types, and design principles, to guide the construction of an effective and user-friendly dashboard for Keytruda's commercial analysis.
Overall, this project offers a valuable roadmap for constructing an efficient Microsoft Power BI-based dashboard that enhances Keytruda's commercial decision-making processes, ensuring better healthcare outcomes for cancer patients and sustainable business growth for MSD.Administrador (a) de EmpresasPregrad
Plan de Comunicaciones Integradas de Marketing (CIM) para el programa de visita médica remota en Merck, Sharp and Dohme (MSD Colombia)
No full text150 Páginas.El presente trabajo de grado tiene como propósito identificar los componentes de un plan de comunicaciones integradas de marketing, aplicado al proyecto de visita médica remota en Merck Sharp and Dohme -MSD-, desde la perspectiva de las Comunicaciones Integradas de Marketing, con el objetivo de promover en los grupos de interés, el uso, conocimiento y aceptación de la visita médica remota
Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study
No full textPublisher Copyright: © 2022, The Author(s).Introduction: Increased mortality has been reported in the Latin American population. The objective is to compare the clinical characteristics and outcome of Latin American and Spanish populations in a cohort of patients hospitalized with COVID-19 during the first year of the pandemic. Methods: We retrospectively analysed all the Latin American patients (born in South or Central America) hospitalized in our centre from February 2020 to February 2021 and compared them with an age- and gender-matched group of Spanish subjects. Variables included were demographics, co-morbidities, clinical and analytical parameters at admission and treatment received. The primary outcomes were ICU admission and mortality at 60 days. A conditional regression analysis was performed to evaluate the independent baseline predictors of both outcomes. Results: From the 3216 patients in the whole cohort, 216 pairs of case-controls (Latin American and Spanish patients, respectively) with same age and gender were analysed. COPD was more frequent in the Spanish group, while HIV was more prevalent in the Latin American group. Other co-morbidities showed no significant difference. Both groups presented with similar numbers of days from symptom onset, but the Latin American population had a higher respiratory rate (21 vs. 20 bpm, P = 0.041), CRP (9.13 vs. 6.22 mg/dl, P = 0.001), ferritin (571 vs. 383 ng/ml, P = 0.012) and procalcitonin (0.10 vs. 0.07 ng/ml, P = 0.020) at admission and lower cycle threshold of PCR (27 vs. 28.8, P = 0.045). While ICU admission and IVM were higher in the Latin American group (17.1% vs. 13% and 9.7% vs. 5.1%, respectively), this was not statistically significant. Latin American patients received remdesivir and anti-inflammatory therapies more often, and no difference in the 60-day mortality rate was found (3.2% for both groups). Conclusion: Latin American patients with COVID-19 have more severe disease than Spanish patients, requiring ICU admission, antiviral and anti-inflammatory therapies more frequently. However, the mortality rate was similar in both groups.This work was financed by ad hoc patronage funds for research on COVID-19 from donations from citizens and organizations to the Hospital Clínic de Barcelona-Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain. No funding or sponsorship was received for the publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Rodrigo Alonso and Ana M. Camon both were responsible for reviewing the data, and they prepared the database including the matching analysis as well as a first draft of the article. Celia Cardozo, Laia Albiach, Daiana Agüero, M. Angeles Marcos, Juan Ambrosioni, Marta Bodro, Mariana Chumbita, Lorena de la Mora, Nicole Garcia-Pouton, Gerard Dueñas, Marta Hernandez-Meneses, Alexy Inciarte, Genoveva Cuesta, Fernanda Meira, and Laura Morata made significant contributions to the manuscript. Pedro Puerta-Accalde, Sabina Herrera, and Gemma Sanjuan performed the statistical analysis and made significant contributions to the final manuscript. Montse Tuset, Pedro Castro, Sergio Prieto-Gonzalez, Josep Mensa, and José Antonio Martínez collaborated on the design of the study and critically reviewed the article. J.M. Nicolas, A. Del Rio, Jordi Vila, Felipe Garcia, Carolina Garcia-Vidal, and Alex Soriano were responsible for the design of the study and made significant contributions to the final version of the article. Alex Soriano, as the corresponding author, answered the reviewers' questions. Hospital Clinic of Barcelona COVID-19 Research Group: Infectious Diseases’ Research Group : J. L. Blanco, J. Mallolas, E. Martínez, M. Martínez, J. M. Miró, A. Moreno, M. Solá, A. Ugarte, Ana Gonzalez-Cordón, Montse Laguno, Lorna Leal, John Rojas, Berta Torres, and all the staff members. Medical Intensive Care Unit : S. Fernandez, A. Tellez, F. Fuentes, E. Sancho, M. Ayala. Department of International Health : D. Campubri, M. T. de Alba, M. Fernandez, E. Ferrer, B. Grau, H. Marti, M. Muelas, M. J. Pinazo, N. Rodriguez, M. Roldan, C. Subira, I. Vera, N. Williams, A. Almuedo-Riera, J. Muñoz, and all the staff members. Department of Internal Medicine : A. Aldea, M. Camafort, J. Calvo, A. Capdevila, F. Cardellach, I. Carbonell, E. Coloma, A. Foncillas, R. Estruch, M. Feliu, J. Fernández-Solá, I. Fuertes, C. Gabara, I. Grafia, A. Ladino, R. López-Alfaro, A. López-Soto, I. Macaya, F. Masanés, A. Matas, M. Navarro, J. Marco-Hernández, L. Miguel, J. C. Milisenda, P. Moreno, J. Naval, D. Nicolás, H. Oberoi, J. Padrosa, S. Prieto-González, M. Pellicé, J. Ribot, O. Rodríguez-Núnez, E. Sacanella, F. Seguí, C. Sierra, A. Tomé, M. Torres, H. Ventosa, C. Zamora-Martínez, and all the staff members. Department of Microbiology : M. Almela, M. Alvarez, J. Bosch, J. Costa, G. Cuesta, B. Fidalgo, J. Gonzàlez, F. Marco, S. Narvaez, C. Pitart, E. Rubio, A. Vergara, M. E. Valls, Y. Zboromyrska and all the staff members. Department of Farmacy : E. López, and all the staff members. Carol García-Vidal has received honoraria for talks on behalf of Gilead Science, MSD, Novartis, Pfizer, Jannsen, and Lilly, as well as a grant from Gilead Science and MSD. Laura Morata has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer and Angelini. Pedro Puerta-Alcalde has received honoraria for talks on behalf of Gilead Science and MSD. Montse Tuset has received grants from Janssen, Gilead, ViiV and Merck Sharp and Dohme. Josep Mensa has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer, Novartis and Angelini. Álex Soriano has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer, Novartis, Gilead, Menarini and Angelini as well as grant support from Pfizer and Gilead. Rodrigo Alonso, Ana M Camón, Celia Cardozo, Laia Albiach, Daiana Agüero, M Ángeles Marcos, Juan Ambrosioni, Marta Bodro, Mariana Chumbita, Lorena de la Mora, Nicole García-Pouton, Gerard Dueñas, Marta Hernández-Meneses, Alexy Inciarte, Genoveva Cuesta, Fernanda Meira, Sabina Herrera, Pedro Castro, Sergio Prieto-González, Jose Antonio Martínez, Gemma Sanjuan, Josep María Nicolás, Ana del Río, Jordi Vila and Felipe García have nothing to disclose. The Institutional Ethics Committee of Hospital Clinic of Barcelona approved the study and, due to the nature of the retrospective data review, waived the need for informed consent from individual patients (HCB/2020/0273). The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.Peer reviewe
High time-resolution tracking and MSD analysis of particle movement.
No full text<p>(A) PRV 483 infected cells were imaged at a rate of 25–50 frames/second, and particles were tracked before and after exocytosis. Graph shows one representative particle track, color-coded to indicate relative gM-pHluorin fluorescence. The location of gM-pHluorin dequenching is indicated (arrow). Bracketed regions correspond to pattern of movement indicated in <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1004535#ppat-1004535-g002" target="_blank">Figure 2E and F</a>: (2) Terminal pause. (3) Sharp jerk. (4) Mostly immobile. (B) Average MSD curves of particle tracks before and after exocytosis. Based on slope and MSD values, particles are confined an area approximately 400 nm in diameter before and after exocytosis (n = 43 exocytosis events, in 9 cells, in 3 independent experiments). Dotted MSD curve represents particles immobilized on glass (n = 249 particles). Shaded areas represent standard error of the mean.</p
Plan de acción para implementar endobranding como estrategia de posicionamiento del punto designado de contacto (dpoc) en el cliente interno de Merck Sharp and Dohme, Colombia (MSD)
No full textEl trabajo que se realizó consistió en la implementación de una campaña de branding interno con el propósito de posicionar en la mente del cliente interno la marca DPOC, que corresponde a un área de la empresa MSD. La anterior oportunidad de mejora se detectó luego de un exhaustivo diagnóstico del área de campo y se desarrolló luego de un trabajo de comunicación y de diseño idóneo. El presente trabajo de grado arroja como resultado final, la implementación de endobranding logró el posicionamiento del Punto Designado de Contacto (DPOC) en el cliente interno de Merck Sharp and Dohme, Colombia (MSD). Además se concluyó que para su ejecución fue necesario el desarrollo de un plan de acción organizado, estructurado y aliado con el Departamento de Comunicaciones, con el fin de establecer las bases necesarias para mitigar los problemas encontrados y alcanzar los resultados deseados.The work performed consisted in implementing internal branding campaign with the purpose of positioning the brand DPOC in the internal customer mind. It corresponds to an area of the company MSD. The improvement opportunity mentioned is detected after a thorough diagnosis of the field area and then developed a communication work and suitable design. This paper throws as a final result, implementation of endobranding achieved the positioning of the Designated Point of Contact (COPD) in the internal client from Merck Sharp and Dohme, Colombia (MSD). In addition, it was concluded that it was necessary for execution developing an action plan organized, structured and allied with the Department of Communications. It was in order to establish the foundation needed to alleviate the problems found and achieve the desired results
Integration of metallic source/drain (MSD) contacts in nanoscaled CMOS technology
No full textAn overview of metallic source/drain (MSD) contacts in nanoscaled MOSFET technology is provided in this paper. MSD contacts offer several benefits for nanoscaled CMOS, i.e., extremely low S/D parasitic resistance, abruptly sharp junctions between S/D and channel and preferably low temperature processing. In order to achieve high performance MSD MOSFETs, many design parameters such as Schottky barrier height (SBH), S/D to gate underlap, top Si layer thickness, oxide thickness and so on should be optimized. Recently, a lot of efforts have been invested in MSD MOSFETs based on Pt- and Ni-silicide implementation and several promising results have been reported in literature. The experimental work as well as the results of Monte Carlo simulations by this research team and by other research teams is discussed in this paper. It will be shown that the present results place MSD MOSFETs as a competitive candidate for future generations of CMOS technology.</p
Log-log profiles of the ensemble-averaged MSD under different self-crowding conditions and CRO densities.
No full textThe profile of variation in natural logarithm of the ratio of ensemble-averaged MSD to time,log (〈r2〉/t), with respect to the natural logarithm of time, log (t), is referred here as the log-log profile for simplicity. (A-G) Each plot demonstrates the log-log profiles of MSD across the increasing CRO density for a given condition of self-crowding. Perfectly normal diffusion is characterized by a flat or horizontal log-log profile across the entire duration of MSD measurement. However, profiles exhibiting sharp linear decrease at longer time characterize strongly anomalous sub-diffusion or confined diffusion and indicate the original dependence of MSD on time raised to a fractional power (power-law relation). There are profiles too which show transition from anomalous to normal diffusion. Evidently, tracer diffusion is observed to be confined and strongly anomalous at higher densities of CROs and DTs.</p
- …
